AIQ Solutions Awarded $2M Phase II NIH SBIR Grant to Advance Development and Commercialization of a Biomarker Technology that Predicts Cancer Immunotherapy Response

AIQ Solutions has been awarded a $2,000,000 Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop and commercialize novel technology for analysis and prediction of treatment response in patients with metastatic cancer treated with immunotherapy

 

PRESS RELEASE – FOR IMMEDIATE DISTRIBUTION


May 3, 2022

 

 

AIQ Solutions Awarded $2M Phase II NIH SBIR Grant to Advance Development and Commercialization of a Biomarker Technology that Predicts Cancer Immunotherapy Response

 

AIQ Solutions has been awarded a $2,000,000 Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute(NCI) of the National Institutes of Health (NIH) to develop and commercialize novel technology for analysis and prediction of treatment response in patients with metastatic cancer treated with immunotherapy. Immunotherapy can be highly effective for a variety of cancers, including those that are difficult to treat, but less than 30% of patients respond to it and ~60% of patients experience significant life-threatening side effects. The ability to better predict which patients will benefit from immunotherapy will provide oncologists with timely, actionable information to optimally balance benefits and risks.

 

AIQ has developed TRAQinform IQ, a medical software technology based on advanced analytics, including artificial intelligence, to revolutionize evaluation of treatment response in patients with complex diseases.  TRAQinform IQ technology is strongly differentiated from competitors by quantifying how each individual region of interest is responding to treatment. The core technology received FDA clearance in 2018 and is protected as intellectual property through multiple issued patents.  This SBIR award provides resources to advance the TRAQinform IQ technology to include a comprehensive analysis of immunotherapy response, prediction of treatment outcomes and identification of early signals of toxicity in healthy organs.

 

According to Eric Horler, President and CEO of AIQ, “Immunotherapy is transforming cancer care, but it only works in a subset of the population and is very costly for the health care system. Prediction of which patients will have a positive overall response to therapy as well as which patients are at elevated risk of treatment-related adverse events has the potential to improve both the clinical effectiveness and overall economics of immunotherapy treatment.”

 

AIQ Solutions, part of AIQ Global Inc., develops biomarkers to better evaluate and predict treatment response for complex diseases, starting with late-stage cancers. The company is headquartered in Madison, Wisconsin, with business operations in the United States and Australia.